the abcellera biologics ( acc ) company is a new and promising industry industry that is a major frontier in the field of drug discovery. we have developed a unique business model that can accelerate drug discovery across the industry. we have developed a unique business strategy that can accelerate drug discovery across the industry, and we believe that this is best accomplished by partnerships. we have developed a unique business approach that can accelerate drug discovery across the industry ; and we have developed a unique business model that is centered around partnerships. we have developed a unique approach to the industry and we believe that this is best accomplished by combining proprietary technologies and tools to generate massive antibody datasets. we believe that this approach can be used to increase the speed and speed of our technology and our business model. we believe that this is best accomplished by a partnership model. we continue to invest in our platform and build capacity, including almost doubling our headcount and acquiring key technologies including a proprietary humanized rodent platform and a bispecific engineering platform. we also secured funding for and began work on the buildup of cement cement andgm manufacturing capabilities. finally, we ended the year with nearly $600 million in cash and over 200 million in accounts receivable. this provides a strong cash position which we will execute our plan for future growth.